Adding Daratumumab Injection Boosts PFS in Myeloma

(MedPage Today) -- Adding subcutaneous daratumumab (Darzalex Faspro) to pomalidomide (Pomalyst) and dexamethasone nearly doubled progression-free survival (PFS) for relapsed multiple myeloma, according to data from a randomized trial presented...